Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Efficacy and Safety of Quarter-Dose Blood Pressure-Lowering Agents: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    Access Status
    Fulltext not available
    Authors
    Bennett, A.
    Chow, C.
    Chou, M.
    Dehbi, H.
    Webster, R.
    Salam, A.
    Patel, A.
    Neal, B.
    Peiris, D.
    Thakkar, J.
    Chalmers, J.
    Nelson, M.
    Reid, Christopher
    Hillis, G.
    Woodward, M.
    Hilmer, S.
    Usherwood, T.
    Thom, S.
    Rodgers, A.
    Date
    2017
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Bennett, A. and Chow, C. and Chou, M. and Dehbi, H. and Webster, R. and Salam, A. and Patel, A. et al. 2017. Efficacy and Safety of Quarter-Dose Blood Pressure-Lowering Agents: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Hypertension. 70 (1): pp. 85-93.
    Source Title
    Hypertension
    DOI
    10.1161/HYPERTENSIONAHA.117.09202
    ISSN
    0194-911X
    School
    Department of Health Policy and Management
    URI
    http://hdl.handle.net/20.500.11937/54481
    Collection
    • Curtin Research Publications
    Abstract

    There is a critical need for blood pressure-lowering strategies that have greater efficacy and minimal side effects. Low-dose combinations hold promise in this regard, but there are few data on very-low-dose therapy. We, therefore, conducted a systematic review and meta-analysis of randomized controlled trials with at least one quarter-dose and one placebo and standard-dose monotherapy arm. A search was conducted of Medline, Embase, Cochrane Registry, Food and Drug Administration, and European Medicinal Agency websites. Data on blood pressure and adverse events were pooled using a fixed-effect model, and bias was assessed using Cochrane risk of bias. The review included 42 trials involving 20 284 participants. Thirty-six comparisons evaluated quarter-dose with placebo and indicated a blood pressure reduction of -4.7/-2.4 mm Hg (P < 0.001). Six comparisons were of dual quarter-dose therapy versus placebo, observing a -6.7/ -4.4 mm Hg (P < 0.001) blood pressure reduction. There were no trials of triple quarter-dose combination versus placebo, but one quadruple quarter-dose study observed a blood pressure reduction of -22.4/-13.1 mm Hg versus placebo (P < 0.001). Compared with standard-dose monotherapy, the blood pressure differences achieved by single (37 comparisons), dual (7 comparisons), and quadruple (1 trial) quarter-dose combinations were +3.7/+2.6 (P < 0.001), +1.3/-0.3 (NS), and -13.1/-7.9 (P < 0.001) mm Hg, respectively. In terms of adverse events, single and dual quarter-dose therapy was not significantly different from placebo and had significantly fewer adverse events compared with standard-dose monotherapy. Quarter-dose combinations could provide improvements in efficacy and tolerability of blood pressure-lowering therapy.

    Related items

    Showing items related by title, author, creator and subject.

    • Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review
      Chow, C.; Thakkar, J.; Bennett, A.; Hillis, G.; Burke, M.; Usherwood, T.; Vo, K.; Rogers, K.; Atkins, E.; Webster, R.; Chou, M.; Dehbi, H.; Salam, A.; Patel, A.; Neal, B.; Peiris, D.; Krum, H.; Chalmers, J.; Nelson, M.; Reid, Christopher; Woodward, M.; Hilmer, S.; Thom, S.; Rodgers, A. (2017)
      © 2017 Elsevier Ltd Background Globally, most patients with hypertension are treated with monotherapy, and control rates are poor because monotherapy only reduces blood pressure by around 9/5 mm Hg on average. There is ...
    • Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease.
      Lonn, E.; Bosch, J.; López-Jaramillo, P.; Zhu, J.; Liu, L.; Pais, P.; Diaz, R.; Xavier, D.; Sliwa, K.; Dans, A.; Avezum, A.; Piegas, L.; Keltai, K.; Keltai, M.; Chazova, I.; Peters, R.; Held, C.; Yusoff, K.; Lewis, B.; Jansky, P.; Parkhomenko, A.; Khunti, K.; Toff, W.; Reid, Christopher; Varigos, J.; Leiter, L.; Molina, D.; McKelvie, R.; Pogue, J.; Wilkinson, J.; Jung, H.; Dagenais, G.; Yusuf, S.; HOPE-3 Investigators (2016)
      BACKGROUND: Antihypertensive therapy reduces the risk of cardiovascular events among high-risk persons and among those with a systolic blood pressure of 160 mm Hg or higher, but its role in persons at intermediate risk ...
    • Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
      Yusuf, S.; Bosch, J.; Dagenais, G.; Zhu, J.; Xavier, D.; Liu, L.; Pais, P.; López-Jaramillo, P.; Leiter, L.; Dans, A.; Avezum, A.; Piegas, L.; Parkhomenko, A.; Keltai, K.; Keltai, M.; Sliwa, K.; Peters, R.; Held, C.; Chazova, I.; Yusoff, K.; Lewis, B.; Jansky, P.; Khunti, K.; Toff, W.; Reid, Christopher; Varigos, J.; Sanchez-Vallejo, G.; McKelvie, R.; Pogue, J.; Jung, H.; Gao, P.; Diaz, R.; Lonn, E.; HOPE-3 Investigators (2016)
      BACKGROUND: Previous trials have shown that the use of statins to lower cholesterol reduces the risk of cardiovascular events among persons without cardiovascular disease. Those trials have involved persons with elevated ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.